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RCC is considered a highly immunogenic tumor responding to anti-angiogenetic TKI and immunotherapy. A better understanding of the 
functions of immune cells in RCC, the immune-modulatory effects of TKIs treatment as well as defining patients most likely to benefit to the 
different therapies will be crucial to optimize combined or sequential immunotherapeutic approaches in RCC patients. 
Methods:
Monocyte derived Dendritic Cells (DCs) from 10 healthy donors were differentiated in presence of Pazopanib and Sunitinib used at plasmatic 
equivalent concentration (Sigma-Aldricht). At the end of the culture, DCs were characterized for marker expression, endocytosis, signal 
transduction and microvesicle release. Similarly, DCs derived from RCC patients were analyzed together with circulating T cells before and 
during TKI treatments. 
Results:
Pazopanib and Sunitinib differently affect DC differentiation. Pazopanib, but not Sunitinib, strongly improves DC performance as antigen-
presenting cells, promoting the upregulation of the maturation markers HLA-DR (+1,5 fold increase compared to Sunitinib-treated DCs), 
CD40 (+3 fold increase) and CCR7 (+2 fold increase) a decrease in phagocytosis and the inhibition of pERK1/2 signaling. 99% of Sunitinib-DCs 
expressed PD-L1 vs 80% Pazopanib-DCs , with a higher expression of the receptor as indicated by mean fluoresce intensity (MFI fold 
increase of +2,1). Similar results were obtained analyzing shedded microvesicles. Results were confirmed in DCs differentiated from RCC 
patients during Pazopanib treatment (before and at 30 and 60 days) and suggest a reverse of the tumor induced immunosuppression. 
Moreover, only Pazopanib treatment appears to induce in these patients a defined circulating CD4  T cell population highly expressing 
CD137 molecule (%CD4 CD137 : T :0,3; T : 4,7; T :29,4). 
Conclusions:
TKIs can affect immunity in RCC patients. In particular, Pazopanib appears to function as a potent activator of DCs in vitro and in vivo 
associated with the neo-activation of a CD137+ T cell population. These results can guide for designing novel protocols to combine TKIs with 
immunoregulatory receptors targeting in RCC.
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